EuroEyes International Eye Clinic Limited (1846) AI Stock Analysis

• Market Cap: HK$1.02B
• Dividend Yield: 1.92%
• Average Volume (3M): 221.59K
• Price to Earnings (P/E): 13.5
• Beta (1Y): 0.25
• Revenue Growth: -1.61%
• EPS Growth: -27.39%
• Country: HK
• Employees: 322
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.12
• Shares Outstanding: 320,706,000
• 10 Day Avg. Volume: 165,100
• 30 Day Avg. Volume: 221,586
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$3.50
• Price Target Upside: 9.72% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 69 Neutral
• Price Target: HK$3.50 ▲(9.72% Upside)

The overall stock score is driven by solid financial performance with strong revenue growth and a robust balance sheet, although concerns about declining profit margins and missing cash flow data are notable. Technical analysis suggests a neutral trend, and the valuation appears reasonable with a supportive dividend yield.

EuroEyes International Eye Clinic Limited Business Overview & Revenue Model

Company Description

EuroEyes International Eye Clinic Limited provides vision correction services in Germany, Denmark, and the People's Republic of China. The company offers refractive laser surgery, which include ReLEx SMILE and FemtoLASIK; phakic lens (ICL) surgery; lens exchange surgery comprising the monofocal and trifocal lens exchange surgery; and PRK/LASEK and ICRS implantation services. Its correction services are used for the treatment of myopia, high myopia, presbyopia, and cataract. The company serves mid-to-high income level customers, who primarily seek surgery to treat their myopia; and above 45 years of age, who primarily seek surgery to treat their presbyopia or cataract. It operates consultation centers and clinics for eye treatment and LASIK centers; and sells pharmaceutical products. The company is also involved in the trading of eye clinic equipment and lenses; and ophthalmic equipment renting and spaces operating activities. EuroEyes International Eye Clinic Limited was founded in 1993 and is headquartered in Hamburg, Germany.

How the Company Makes Money

EuroEyes International Eye Clinic Limited generates revenue primarily through the provision of specialized eye surgery procedures. The company's key revenue streams include fees from refractive surgeries such as LASIK and ReLEx SMILE, as well as lens replacement surgeries to treat presbyopia and cataracts. EuroEyes benefits from a strong reputation and partnerships with leading medical equipment manufacturers, leveraging advanced technologies to attract patients seeking high-quality vision correction solutions. Additionally, the company may engage in strategic partnerships and collaborations with healthcare providers and insurance companies to expand its market reach and service offerings.

EuroEyes International Eye Clinic Limited Financial Statement Overview

Summary

EuroEyes International Eye Clinic Limited showcases strong revenue growth and low leverage, evidenced by increasing revenue and a low Debt-to-Equity Ratio of 0.29. However, declining profit margins and missing cash flow data for 2024 raise concerns about cost management and cash generation capabilities.

Income Statement

The company shows a consistent revenue growth trajectory, with revenue increasing from HK$427.2M in 2019 to HK$715.7M in 2024, indicating strong demand for its services. The Gross Profit Margin has slightly decreased from 47.8% in 2023 to 40.1% in 2024, suggesting some pressure on cost management. The Net Profit Margin also decreased from 18.4% to 11.5%. Despite these declines, EBIT and EBITDA margins remained reasonably robust, reflecting effective operational management.

Balance Sheet

The company maintains a strong equity position with an Equity Ratio of roughly 68.3% in 2024, indicating financial stability. The Debt-to-Equity Ratio is relatively low at 0.29, suggesting low leverage and reduced financial risk. However, a slight decline in Stockholders' Equity from 2023 to 2024 could be a potential concern if it continues.

Cash Flow

The lack of reported Operating Cash Flow and Free Cash Flow in 2024 raises concerns about the company's cash generation capabilities. In prior years, there was positive Free Cash Flow, indicating previously healthy operations. The absence of cash flow data for 2024 could signal potential operational or financial challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	715.68M	714.29M	610.29M	632.93M	473.82M
Gross Profit	286.59M	335.52M	270.84M	312.55M	214.10M
EBITDA	141.89M	292.10M	220.44M	278.80M	173.62M
Net Income	82.28M	131.24M	89.47M	133.56M	65.58M
Balance Sheet
Total Assets	1.60B	1.75B	1.54B	1.37B	1.31B
Cash, Cash Equivalents and Short-Term Investments	680.67M	720.38M	779.57M	861.58M	761.89M
Total Debt	319.29M	384.26M	290.41M	221.48M	239.55M
Total Liabilities	473.72M	588.09M	497.95M	328.55M	324.57M
Stockholders Equity	1.09B	1.13B	1.01B	1.01B	953.29M
Cash Flow
Free Cash Flow	117.41M	102.30M	152.46M	228.71M	40.12M
Operating Cash Flow	197.75M	191.85M	208.76M	273.26M	78.46M
Investing Cash Flow	-83.83M	-180.28M	-131.81M	-59.90M	-38.13M
Financing Cash Flow	-136.82M	-102.76M	-102.22M	-69.18M	-116.37M

EuroEyes International Eye Clinic Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1846, the sentiment is Positive. The current price of 3.19 is above the 20-day moving average (MA) of 3.09, above the 50-day MA of 3.13, and above the 200-day MA of 3.15, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 54.43 is Neutral, neither overbought nor oversold. The STOCH value of 71.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1846.

EuroEyes International Eye Clinic Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3689	71 Outperform	HK$662.10M	8.02	1.07%	8.08%	0.47%	50.46%
1846	69 Neutral	HK$1.02B	13.51	6.35%	1.92%	-1.61%	-27.39%
2219	68 Neutral	HK$1.84B	9.68	8.42%	9.62%	-3.19%	-20.30%
6639	52 Neutral	HK$1.15B	44.25	1.28%	―	-4.30%	13.83%
3869	48 Neutral	HK$950.77M	6.54	―	―	2.30%	―
3309	46 Neutral	HK$2.36B	-19.83	-7.71%	1.06%	2.05%	-285.88%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

EuroEyes International Eye Clinic Limited Corporate Events

EuroEyes Expands European Operations with Strategic Acquisitions

EuroEyes International Eye Clinic Limited has announced the acquisition of assets in Switzerland and the United Kingdom through its subsidiaries. The acquisitions include medical clinics and related assets for refractive surgery, with the Swiss assets valued at CHF12,010,000 and the UK assets at CHF200,000. These transactions are considered discloseable under the Hong Kong Stock Exchange Listing Rules, indicating a strategic expansion in EuroEyes’ operational capacity and market presence in Europe.

The most recent analyst rating on (HK:1846) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on EuroEyes International Eye Clinic Limited stock, see the HK:1846 Stock Forecast page.

EuroEyes Announces Interim Results for First Half of 2025

EuroEyes International Eye Clinic Limited has announced its unaudited interim results for the first half of 2025. This announcement, which complies with the listing requirements of the Hong Kong Stock Exchange, provides stakeholders with insights into the company’s financial performance and operational status during this period.

The most recent analyst rating on (HK:1846) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on EuroEyes International Eye Clinic Limited stock, see the HK:1846 Stock Forecast page.

EuroEyes Establishes Board Nomination Committee to Enhance Governance

EuroEyes International Eye Clinic Limited has established a nomination committee within its board of directors, as per a resolution passed on August 28, 2025. This committee is tasked with overseeing the nomination process for board members, ensuring diversity and independence, which could enhance governance and strategic decision-making within the company.

The most recent analyst rating on (HK:1846) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on EuroEyes International Eye Clinic Limited stock, see the HK:1846 Stock Forecast page.

EuroEyes Declares Interim Dividend for H1 2025

EuroEyes International Eye Clinic Limited has announced an interim cash dividend of HKD 0.0315 per share for the six months ending June 30, 2025. This move signifies the company’s stable financial performance and commitment to returning value to its shareholders, potentially enhancing its market position and investor confidence.

The most recent analyst rating on (HK:1846) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on EuroEyes International Eye Clinic Limited stock, see the HK:1846 Stock Forecast page.

EuroEyes Announces Executive Management Changes

EuroEyes International Eye Clinic Limited has announced a series of changes in its executive management and board composition. Dr. Markus Braun has resigned as Executive Director and CFO, effective September 2025, to pursue personal career development. He will be succeeded by Mr. Marcus Huascar Bracklo, who has been re-designated from a non-executive to an executive director and appointed as the new CFO. Mr. Bracklo brings over 25 years of experience in the healthcare sector, specializing in corporate finance and mergers and acquisitions, which is expected to positively impact the company’s strategic and financial development.

The most recent analyst rating on (HK:1846) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on EuroEyes International Eye Clinic Limited stock, see the HK:1846 Stock Forecast page.

EuroEyes Announces New Board of Directors and Roles

EuroEyes International Eye Clinic Limited has announced the updated list of its board of directors and their roles, effective from September 14, 2025. This reorganization includes both executive and independent non-executive directors, with specific members assigned to the audit, remuneration, and nomination committees. This strategic update is likely to impact the company’s governance and operational oversight, potentially influencing its market positioning and stakeholder relations.

The most recent analyst rating on (HK:1846) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on EuroEyes International Eye Clinic Limited stock, see the HK:1846 Stock Forecast page.

EuroEyes Announces Board Meeting to Review Interim Results

EuroEyes International Eye Clinic Limited has announced that its board of directors will meet on August 28, 2025, to review and approve the interim financial results for the first half of the year, consider the recommendation of an interim dividend, and address other business matters. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and strategic decisions, potentially impacting its market positioning and shareholder value.